National Audubon Society Board of Directors Elects Dr. George Golumbeski as Chairman [Yahoo! Finance]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
“George's long-standing leadership and dedication to Audubon will serve us well,” said Dr. Elizabeth Gray, CEO of the National Audubon Society. “As we continue to expand our hemispheric work, George's insights will be invaluable as we strive to ‘bend the bird curve'—halting and ultimately reversing the decline of bird populations across the Americas. Together, we will continue advancing Audubon's bold, science-driven solutions, fueled by our non-partisan approach, to create a future where birds, people, and the planet thrive. I am also grateful for Susan's leadership as Chair these past few years.” George Golumbeski has served on Audubon's Board of Directors since 2015. In 2017 he was elected Treasurer of the Board, and since 2021 he has served as Vice Chair. Golumbeski is a molecular biologist and biotechnology executive currently working as a partner at DROIA Ventures. He has held a variety of leadership positions at pharmaceutical companies including Celgene, Novartis, Elan Ph
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis SuppurativaPR Newswire
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]Yahoo! Finance
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial SpondyloarthritisPR Newswire
- Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]Seeking Alpha